Lipoxygenase inhibition: The neglected frontier for regulating chronic inflammation and pain

Inflammopharmacology

Volumn 14, Issue 3-4, 2006, Pages 99-102

  Whitehouse, M W ^a   Rainsford, K D ^b  

^a GRIFFITH UNIVERSITY   (Australia)

^b SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

Author keywords

'Steroid sparing'; 5 lipoxygenase; Corticosteroid; Emu oil(s); Lyprinol ; Synergy

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 3 [6 [7 CYANO 5 (3 FURYL) 2 NAPHTHOXYMETHYL] 2 PYRIDYL] 3 HYDROXY 6,8 DIOXABICYCLO[3.2.1]OCTANE; ACETYLSALICYLIC ACID; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE; BENOXAPROFEN; BOSWELLIC ACID; CORTICOSTEROID; CURCUMIN; CYCLOOXYGENASE 2 INHIBITOR; DIFLUNISAL; DROMAIOL; ETORICOXIB; ICOSATETRAYNOIC ACID; LIPOXYGENASE INHIBITOR; LYPRINOL; MONTELUKAST; NONSTEROID ANTIINFLAMMATORY AGENT; NORDIHYDROGUAIARETIC ACID; PARACETAMOL; PENTOXIFYLLINE; PLANT EXTRACT; PREDNISONE; ROFECOXIB; SALAZOSULFAPYRIDINE; SALICYLIC ACID; STEROID; UNCLASSIFIED DRUG; UNINDEXED DRUG; WITHANIA EXTRACT; ZILEUTON;

ACUTE PANCREATITIS; ASTHMA; CHRONIC INFLAMMATION; CHRONIC PAIN; DRUG MECHANISM; EDITORIAL; ENTERITIS; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER DISEASE; MOON FACE; NONHUMAN; OSTEOARTHRITIS; OSTEOPOROSIS; PATHOGENESIS; PERITONITIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCLERODERMA; SEPTIC SHOCK; SKIN DISEASE; STOMACH DISEASE;

EID: 33748514575     PISSN: 09254692     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10787-006-1523-7     Document Type: Editorial

References (48)

1. Ahmadzadeh, N., Shingu, M., Nobunaga, M., Tawara, T. (1991). Relationship between leukotriene B4 and immunological parameters in rheumatoid synovial fluids. Inflammation (NY), 15: 497-503.
2. 2 and epinephrine in the rat. Exp Brain Res, 148: 482-7.
3. rd Edition, St Louis, MO. Facts and Comparisons, pp 384-5.
4. Atik, O. S. (1990). Leukotriene B4 and prostaglandin E2-like activity in synovial fluid in osteoarthritis. Prostaglandins, Leukotrienes Essent. Fatty Acids, 39: 253-4.
5. Batt, D. C. (1992). 5-lipoxygenase inhibitors and their anti-inflammatory activities. Progr Med Chem 29: 1-63.
6. Bennett, G., Rahed, S., Hoult, J. R., Brain, S. D. (1998). Nerve growth factor induced hyperalgesia in the rat hindpaw is dependent on circulating neutrophils. Pain, 77: 315-22.
7. Betts, W. H., Turner, A. G. (2006) unpublished clinical studies. [NOTE: This data is to hand but not publishable 'til August, 2006 when KDR visits.]
8. Brain, S. D., Williams, T. J. (1990). Leukotrienes and inflammation. Pharmacol Therap, 46: 57-66.
9. Butters, D. E., Whitehouse, M. W. (2003). Treating inflammation: some (needless) difficulties for gaining acceptance of effective natural products and traditional medicines. Inflammopharmacology, 11: 97-110.
10. Chand, S., Sofia, R. D. (1995). Azelastine - a novel in vivo inhibitor of leukotriene biosyntheseis: a possible mechanism of action. J Asthma, 32: 227-34.
11. Colville-Nash, P. R., Gilroy, D. W. (2001). Potential adverse effects of cycloxygenase-2 inhibition: Evidence from animal models of inflammation. Bio Drugs, 15: 1-9.
12. Etzel, R. (1996). Special extract of Boswellia serrata in the treatment of rheumatoid arthritis. Phytomed, 3: 91-4.
13. Ferreira, S. H. (2005). Proposal to use pentoxifylline and Lyprinol therapy for chronic inflammatory diseases. Inflammopharmacology. 13: 429-30.
14. Fiorucci, S., Distrutti, E., Santucci, L., Morelli, A. (1995). Leukotrienes stimulate pepsinogen secretion from guinea pig gastric chief cells by a nitric oxide-dependent pathway. Gastroenterol, 108: 1709-19.
15. Gyömber, E., Vattay, P., Szabo, S., Rainsford, K. D. (1996a). Effect of lipoxygenase inhibitors and leukotriene antagonists on acute and chronic gastric haemorrhagic mucosal lesions in ulcer models in the rat. J Gastroenterol Hepatol, 11: 922-7.
16. Gyömber, E., Vattay, P., Szabo, S., Rainsford, K. D. (1996b). Role of early vascular damage in the pathogenesis of gastric haemorrhagic mucosal lesions induced by indomethacin in rats. Int J Exp Pathol 77, 1-6.
17. Gyires, K. (1994). Some of the factors that may mediate or modify the gastrointestinal mucosa damage induced by non-steroidal anti-inflammatory drugs. Agents Actions, 41: 73-9.
18. Halpern, G. M. The inflammation revolution: a natural solution for arthritis, asthma and other inflammatory disorders. Golden City Park, N.Y. Squareone Publ., 2005, 127 pp.
19. Harbison, S. J., Whitehouse, M. W. (2000). Possible steroid-sparing effect in asthma of Lyprinol, a shellfish lipid extract. Med J Austr, 173: 560.
20. Jala, V. R., Haribabu, B. (2004). Leukotrienes and arthrosclerosis: new roles for old mediators. Trends Immunol, 20: 315-22.
21. Jaramillo, E., Mardh, S., Green, K., Persson, B., Rubio, C., Aly, A. (1989). The effect of arachidonic acid and its metabolites on acid production in isolated human parietal cells. Scand J Gastroenterol, 24: 1231-7.
22. Konturek, S. J., Bilski, J., Dembinski, A., Warzecha, A., Beck, G., Jendralla, H. (1987). Effects of leukotrienes on gastric acid and alkaline secretions. Gastroenterology, 92(5 Pt 1): 1209-14.
23. Kolaczkowska, E. (2002). Shedding light on vascular permeability during periotonitis: row of masked cell histamine versus cysteinyl leukotrienes. Inflamm Res. 51: 519-21.
24. Kowal-Bielecka, O., Distler, O., Neidhart, M., Kunzler, P., Rethage, J., Nawrath et al. (2001). Evidence of 5-lipoxygenase overexpression in the skin of patients with systemic sclerosis. Arthritis Rheum, 44: 1865-75.
25. Leval, X., Julemont, F., Delarge, J., Pirotte, B., Dogne, J. M. (2002). New trends in dual 5-LOX/COX inhibition. Curr Med Chem, 9: 941-62.
26. Lutnicki, K., Szpringer, E., Czerny, K., Ledwozyw, A. (2001). Effects of ethanol and arachidonic acid pathway inhibitors on the effectiveness of gastric mucosa cytoprotection. Folia Morphol (Warsaw), 60: 47-56.
27. Pendleton, R. G., Shepherd-Rose, A. J., Stavorski, J. M. (1986). Leukotriene effects upon the transgastric potential difference and pepsin secretion. Eur J Pharmacol. 123: 29-36.
28. Magous, R., Bali, J. P., Rossi, J. C., Girard, J. P. (1983). Leukotrienes stimulate acid secretion from isolated gastric parietal cells. Biochem Biophys Res Commun, 114: 897-900.
29. 4 on gastric emptying and secretion in rhesus monkeys. J Pharmacol Exp Ther. 262: 850-4.
30. O'Dell, J. R., Haire, C. E., Erikson, N., Drymalski, W., Palmer, W., Eckhoff, P. J. et al. (1996). Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all 3 medications. N Engl J Med. 334: 1287-91.
31. Rainsford, K. D. (1987). The effects of 5-lipoxygenase inhibitors and leukotriene antagonists on the development of gastric lesions induced by nonsteroidal antiinflammatory drugs in mice. Agents Actions. 21: 316-9.
32. Rainsford, K. D. (1993). Leukotrienes in the pathogenesis of NSAID-induced gastric and intestinal mucosal damage. Agents Actions, 39 Spec No: C24-6.
33. Rainsford, K. D. (1999). Inhibition by leukotriene inhibitors, and calcium and platelet-activating factor antagonists, of acute gastric and intestinal damage in arthritic rats and in cholinomimetic-treated mice. J Pharm Pharmacol, 51: 331-9.
34. Rainsford, K. D. (2001). The ever-emerging anti-inflammatories. Have there been any real advances? J Physiol (Paris), 95: 11-9.
35. Rainsford, K. D., Whitehouse, M. W. (2006). Paracetamol [acetaminophen]-induced gastrotoxicity: revealed by induced hyperacidity in combination with acute or chronic inflammation. Inflammopharmacol. 14: in press. [Note to Production Editor - please insert pages here]
36. 2 group IIA. Curr Med Chem, 12: 3011-26.
37. Schumert, R., Towner, J., Zipser, R. D. (1988). Role of eicosanoids in human and experimental colitis. Dig Dis Sci, 33: 58S-64S.
38. Serhan, C. N., Chiang N. (2004). Novel endogenous small molecules as the checkpoint controllers in inflammation and resolution. Rheum Dis Clin N Am, 30: 69-95.
39. Sharma, J. N., Mohammed, L. A. (2006). The role of leukotrienes in the pathophysiology of inflammatory disorders: Is there a case for revisiting leuktrienes as therapeutic targets? Inflammopharmacology, 14: 10-6.
40. Singh, V. P., Patel, C. S., Kulkarni, S. K. (2005). Differential effect of zileuton, a 5-lipoxygenase inihibitor against nociceptive paradigms in mice and rats. Pharmacol Biochm Behav, 81: 433-9.
41. Stenson, W. F. (1990). Role of eicosanoids as mediators of inflammation in inflammatory bowel disease. Scand J Gastroenterol Suppl, 172: 13-8.
42. Trang, T., McNaull, P., Quirion, R., Jhamandas, K. (2004). Involvement of spinal lipoxygenase metabolites in hyperalgesia and opoid tolerance. Eur J Pharmacol. 491: 21-30.
43. Trnavsky, K., Gatterova, J., Linduskova, M., Peliskova, Z. (1993). Combination therapy with hydroxychloriquin and methotrexate in rheumatoid arthritis. Z Rheumatol, 52: 292-6.
44. Voelkel, N. F., Tuder, R. M., Wade, K., Hoper, M., Lepley, R. A., Goulet, J. L. et al. (1996). Inhibition 5-lipoxygenase - activating protein (FLAP) reduces pulmonary vascular reactivity and pulmonary hypertension in hypoxic rats. J Clin Invest, 97: 2491-8.
45. Whitehouse, M. W. (2005). Unanticipated toxicities: NSAIDs and thiocyanate can each induce arthritis in rats(!), preventing acquisition of tolerance. Proc Austr Soc Clin Exp Pharmacol & Toxicol, 11: Abstract 1-93.
46. Whitehouse, M. W., Turner, A. G., Davis, C. K. C., Roberts, M. S. (1998). Emu oil(s): a source of non-toxic transdermal anti-inflammatory agents in Aboriginal Medicine. Inflammopharmacol, 6: 1-8.
47. Whitehouse, M. W., Butters, D. E. (2003). Combination anti-inflammatory therapy: synergism in rats of NSAIDs/cortiosteroids with some herbal/animal products. Inflammopharmacology, 11: 453-64.
48. Wittenberg, R. H., Willburger, R. E., Kleemeyer, K. S., Peskar, B. A. (1993). In vitro release of prostaglandins and leukotrienes from synovial tissue, cartilage, and bone in degenerative joint diseases. Arthritis Rheum. 36: 1445-50.